Introduction
High-grade fever before engraftment without any other obvious signs of infection, which mimics hyperacute GVHD or engraftment syndrome, is frequently observed in patients who undergo cord blood transplantation (CBT). 1, 2 In previous reports, when patients with no evidence of infection or adverse effects of medication exhibited skin eruption, diarrhea, jaundice or body weight gain greater than 10% of baseline, these conditions were defined as 'immune reactions.' These reactions were classified as 'pre-engraftment immune reaction (PIR)' if they developed 6 or more days before engraftment, whereas those within 5 days of engraftment were defined as 'engraftment syndrome' (1) . The reported incidence of PIR has ranged from 78-83% (1) (2) . This PIR peaks at around day 9 of CBT, and is often accompanied by high-grade fever. Although PIR responds well to corticosteroid therapy, the prolonged use of steroid often causes an increased incidence of infectious complications, leading to significant treatment-related mortality, particularly in the elderly. GVHD prophylaxis with tacrolimus, compared with CsA, is less likely to be associated with PIR 3, 4 and the addition of MTX may further reduce the risk. 5, 6 It has been speculated that cytokines induced by the initial immune/inflammation reaction are the primary cause of PIR, but no data are available to confirm this supposition. To clarify this question, we evaluated the protein expression profile of serum in CBT recipients using a surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI-TOF MS) system and found potential markers for PIR.
Materials and methods

Study patients and samples
Patients who received treatment for hematological malignancies at the National Cancer Center Hospital or Toranomon Hospital between February 2002 and May 2005 were included in this study. The study was approved by the Ethics Committee, and written informed consent was given by all patients. A total of 78 peripheral blood samples taken from 57 patients, including 34 samples taken from 13 patients who had undergone allogeneic CBT, were eligible for the analysis. Samples from CBT patients were taken on three different occasions, that is, (1) afebrile period before PIR onset: the median of day 3 (1-6) post transplant; (2) onset of fever: the median of day 8 (6-13); and (3) after resolution of fever: the median of day 26.5 . To analyze the protein profile that was specific to PIR, samples taken from patients with documented infection or those who were suffering from engraftment syndrome were excluded from the analysis. All 13 CBT patients received reduced-intensity conditioning, and graft rejection occurred in 2 patients (16%). As for the treatment and its outcome for PIR, six patients responded well to corticosteroid and seven patients improved without any treatment or empiric antibiotics alone. One of the patients who developed graft failure received corticosteroids for the treatment of PIR. The mean neutrophil count at PIR was 15 (0-100)/ml. The patients' characteristics are shown in Table 1 .
SELDI-TOF MS analysis
The relative protein expression levels were determined as previously described with the following modifications using a SELDI TOF-MS system (Bio-Rad Laboratories, Hercules, CA, USA). 7, 8 The protein was processed using a Biomek 2000 Laboratory Work Station (Beckman Coulter, Fullerton, CA, USA). Samples were analyzed in duplicate and 28 spectra were obtained from five serum fractions with four kinds of chips (IMAC30, CM10, H50, Q10), four different binding buffers, two kinds of energy absorption molecules and two focus mass ranges.
Serum fractionation
The serum samples were centrifuged at 20 000 Â g and the supernatant was vigorously mixed with denaturation buffer U9 (9 M urea: 2% CHAPS: 50 mM Tris-HCl, pH9) for 20 min. Serum samples were fractionated into four fractions by the following methods. Briefly, the strong anion exchange resin BioSepra Q Ceramic HyperD F (Pall, NY, USA) was equilibrated with 50 mM Tris-HCl, pH 9, in advance, and 180 ml per well was loaded onto a filter plate. The loaded resin was equilibrated three times with 200 ml of U1 buffer (U9 buffer diluted 1:10 with 50 mM Tris-HCl). Denatured serum was added to the resin, the sample well was washed with 50 ml of U1 buffer, and the sample was incubated for 30 min at 4 1C. The non-binding fraction was collected, and protein was eluted by a phased pH gradient at pH 5.8, pH 4 and below pH 4.
Protein binding IMAC30 (immobilized metal affinity capture), CM10 (cation exchange), H50 (reverse-phase) and Q10 (anion exchange) ProteinChip arrays were used for the analysis.
To immobilize copper ion on the IMAC30 surface, each spot was incubated with 50 ml of 100 mM copper sulfate for 10 min at room temperature. Excess copper was removed by washing twice with distilled water and incubated with 50 ml of 100 mM sodium acetate (pH 4) for 5 min at room temperature. Each spot was rinsed twice with distilled water before the analysis step.
The following buffers were used for binding and dilution of the samples: 100 mM sodium acetate (pH 4) or 50 mM HEPES (pH 7) for CM10, 100 mM sodium phosphate (pH 7) þ 0.5 M NaCl for IMAC30, 50 mM HEPES (pH 7) for H50, and 50 mM Tris-HCl (pH 8) for Q10. The following procedure was commonly used for all chip analyses: (1) Each spot was equilibrated twice with 150 ml of binding buffer on a shaker for 5 min, and excess buffer was removed. (2) The fractionated and unfractionated samples were diluted 10-fold with binding buffer. The diluted samples were loaded onto a chip, and incubated on a shaker for 30 min at room temperature. (3) The chip was washed three times on a shaker for 5 min with 150 ml per spot of buffer. (4) The chip was rinsed twice with 200 ml of distilled water and dried. (5) Each spot was treated with two kinds of energy absorption molecules: 50% saturated sinapinic acid and a-cyano-4-hydroxycinnamic acid.
Protein detection
Captured proteins were detected using a ProteinChip SELDI system (PCS4000 Enterprise, Bio-Rad Laboratories). The maximum detection range was 100 000 with a focus mass range of 3000-10 000 for low MW, and 200 000 with a focus mass range of 10 000-30 000 for high MW. Quantitative analysis of proteins was performed using 
Protein purification and identification
The serum samples were denatured with urea and fractionated by an anion exchange column (ProteinChip Q Spin Columns, Bio-Rad Laboratories) to remove albumin by binding it to the column. The fraction that passed through the anion exchange column at pH 9 was collected. The sample was diluted threefold with 50 mM Tris-HCl (pH 8) and loaded onto an anion exchange column to bind the objective peak protein. 
Identification of markers for PIRs after CBT by SELDI-TOF MS
Y Morita-Hoshi et al edition), and the amino-acid sequence was determined using the PCI-QSTAR MS/MS search engine.
Statistical analysis
Data were analyzed using ProteinChip Data Manager Software. After baseline correction, MW calibration was performed using eight standard protein molecules followed by a total ion current normalization process. To identify distinct and significant peaks, we used a signal-to-noise cutoff of 2 (s/n42), which selects peaks with a signal level that is significantly above the calculated background noise. For the statistical analysis, the Kruskal-Wallis H-test was used to compare differences among three groups. The differences between the two groups were compared with the Wilcoxon-Mann-Whitney U-test. Probabilities of Po0.05 were defined as statistically significant.
Results
Protein profiles
A total of 3005 protein peaks for which s/n 42 were detected. Of these, 743 showed a significant difference between the febrile and afebrile periods. After we further excluded noise peaks, 469 peaks still showed a significant difference, and after excluding variations between individuals, 19 candidate peaks that were commonly elevated at PIR in more than 11 patients (84.6%) were selected. Reproducibility was tested, and six protein peaks that commonly increased at the time of PIR, with molecular masses of 8611, 8642, 11452, 11512, 11539 and 11669 Da, were identified (Figure 1 ). The assay conditions under which the proteins were identified are shown in Table 2 .
Purification and determination of target proteins Protein peaks were fractionated by an anion exchange column, and the elution fraction at pH 9 was used for purification and identification because the albumin that overlaps the candidate peak was removed from this fraction. The protein was eluted from the column with 100-150 mM NaCl. SDS-PAGE after demineralization and concentration of the protein showed an 11-kDa band (Figure 2a) . In-gel digestion was performed on the cutout band, and mass fingerprinting was performed for eight peptides with mass values of 1455, 1463, 1550, 1611, 1670, 1706, 1941 and 2097 (Figure 2b ). Six of these values were consistent with serum amyloid A (SAA), which consists of 
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104 amino acids and has a MW of 11 622, or its isoforms, in which serine and/or arginine is deleted from the N-terminal portion ( Figure 3 ). The amino-acid sequences of all six peptide masses were consistent with SAA by MS/MS analysis. The SAA level was measured by ELISA in the same sample that was assessed by SELDI-TOF MS. The mean SAA level measured by ELISA before fever onset was 14 (3-51) mg/ml, and this increased to 883 (40-2470) mg/ml at the time of PIR and decreased to 45 (8-126) mg/ml after resolution of the fever (Figure 4a ). The data obtained by ELISA agreed with the SELDI-TOF MS peak intensity value (Figure 4b) . Although the 8.6 kDa peak was not determined in this experiment, it was most likely to be anaphylatoxin C4a based on its MW (8650) and isoelectric point (9.45).
Serum amyloid A value in different conditions
Seven of the 13 patients with PIR developed acute GVHD, and 2 patients had graft failure. The patients who developed graft failure showed high levels of SAA at PIR (2040 and 2390 mg/ml). The mean and median values of SAA at PIR in seven patients who developed acute GVHD were 677 mg/ml and 451 (60-2470) mg/ml, respectively, which were not significantly different from the values in the four patients without acute GVHD (432 and 506 (40-675) mg/ml) (P ¼ 0.93).
The SAA value was assessed in 24 non-transplant febrile patients: (a) 12 samples from patients with documented infection, including sepsis, (b) 6 samples from patients with tumor fever and (c) 6 samples from patients with druginduced fever. The mean and median values and statistical significance when compared with PIR were (a) 477 mg/ml and 347 (31-1240) mg/ml (P ¼ 0.63), (b) 432 mg/ml and 248 (127-1080) mg/ml (P ¼ 0.75) and (c) 49 mg/ml and 42 (31-73) mg/ml (P ¼ 0.0013), respectively.
The SAA values during acute GVHD in other transplantation settings were assessed in 20 patients: (d) 10 samples from related allo-PBSCT recipients including 5 febrile patients and (e) 10 samples from unrelated BMT recipients including 4 febrile patients. The mean and median values and statistical significance when compared with PIR were (d) 293 and 238 (19-645) mg/ml (P ¼ 0.20) and (e) 366 and 344 (31-724) mg/ml (P ¼ 0.31), respectively (Figure 4a ). The level of SAA elevation was not as high as that in PIR, but the sample size was too small to show specificity.
Discussion
Proteomic analysis has been widely used to assess the allogeneic response, including GVHD in hematopoietic SCT. [8] [9] [10] [11] The two most important methods that are used to investigate biomarkers, for example, detection of early GVHD, are SELDI-TOF MS and capillary zone electrophoresis mass spectrometry (CE-MS). Although the resolution and sensitivity of SELDI-TOF MS are not as high as those of CE-MS, it has the benefits of relatively low cost and ease of use. 9 It has been reported that proteomic pattern analysis by SELDI-TOF MS can be used to accurately distinguish GVHD samples from post transplant non-GVHD samples and pretransplant samples with 100% specificity and 100% sensitivity. 8 Furthermore, with the CE-MS system, 16 polypeptide patterns excreted in the urine could be used to discriminate patients with GVHD from patients without complications, with 82% specificity and 100% sensitivity. In addition, 13 sepsis-specific polypeptides The analyzed peak was determined to be SAA and its isoform produced by the deletion of serine and/or arginine from the N terminus.
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11
Proteomic analysis has also been applied to the analysis of an allograft response in organ transplantation in animal models. 12, 13 In a mouse skin transplant model, several protein biomarker candidates were detected by ProteinChip technology based on their molecular mass, which could be used to clearly differentiate between rejection and nonrejection groups, before a clinical manifestation. 12 In a rat small bowel transplantation model, two migration inhibitory factor-related proteins and lysozyme that increased during allograft rejection were identified by a SELDI-TOF MS system. 13 Thus, we believe that ProteinChip technology should be a useful tool for identifying specific markers related to PIR. Previous studies have shown that combinations of several biomarkers are more sensitive and accurate than the use of a single marker in the diagnosis of an allogeneic response. 11 However, most biomarkers are not well characterized and can only be detected by the ProteinChip system. As the ProteinChip system is not routinely available in clinical practice, we thought it would be necessary to identify a marker that could be monitored easily. In this study, SAA was identified as a candidate marker for PIR. Furthermore, this study showed the feasibility of quantitative analysis by the ProteinChip system, although the ProteinChip system has previously been considered to be a tool for semiquantitative analysis.
Serum biomarkers associated with leukemia 14 and cancer [15] [16] [17] [18] [19] [20] [21] have also been identified by the SELDI Documented infection including sepsis, tumor fever, drug-induced fever, GVHD in related allo-PBSCT (r-PBSCT) and GVHD in unrelated BMT (u-BMT).
(b) The data obtained by ELISA correlated well with the SELDI-TOF MS peak intensity value (n ¼ 34).
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ProteinChip technique. In some of these studies, SAA has been reported to be a potential marker for particular cancer status. Multiple variants of SAA have been detected by the SELDI ProteinChip technique in renal cancer patients. 20 The SELDI ProteinChip technique revealed that SAA may be a biomarker for identifying prostate cancer patients with bone lesions, with a sensitivity and specificity of 89.5%. 21 SAA activates human mast cells, which leads to the degradation of SAA and the generation of an amyloidogenic SAA fragment. 22 SAA is a major acute-phase reactant that increases by as much as 1000-fold during inflammation. SAA is potentially involved in the pathogenesis of several chronic inflammatory diseases: it is the precursor of amyloid A protein deposited in amyloid A amyloidosis, and has also been implicated in the pathogenesis of atherosclerosis and rheumatoid arthritis. 23, 24 SAA may be closely related to poor patient outcomes, including left ventricular systolic dysfunction, cardiac rupture and mortality in acute myocardial infarction. 25, 26 Some studies have suggested that the elevation of SAA may be associated with acute allograft rejection of the kidney, 27-30 liver 31 and heart. 32 By contrast, it has also been reported that SAA is inadequate for predicting acute rejection in cardiac allograft. 33 With regard to renal allograft rejection, SAA was shown to be a sensitive marker that rose above 100 mg/l in all cases of rejection, whereas C-reactive protein (CRP) showed little or no response to rejection. 29 We could not confirm whether or not the elevation of SAA was a phenomenon that occurs with all CBT around day 9, as the value of SAA in samples from non-febrile patients at this time point was not analyzed. However, it is unlikely that the elevation of SAA occurs with all allogeneic transplantation, as the phenomenon was not prominent in patients with acute GVHD. The possibility that the elevation of SAA was only a consequence of acute phase change that occurs with highgrade fever could not be completely ruled out, as the elevation of SAA was not confined to CBT; however, the elevation level was higher in PIR than in other conditions. Furthermore, patients who developed graft rejection had markedly higher levels of SAA. Although the reason for these observations is unclear, a previous report on SAA as an indication of allograft rejection has suggested that inflammation and cytokine production induced by an alloreaction may be related to the elevation of SAA in PIR.
In the case of CBT, SAA that increases in relation to PIR, as a factor associated with a poor prognosis of CBT, may be related to allograft rejection. Our retrospective study showed that pre-engraftment CRP values may predict acute GVHD and nonrelapse mortality. 34 Although CRP elevation was also observed during PIR, SAA elevation was more rapid and prominent. The SAA level was above the normal limit in all 13 samples at the day of fever onset, whereas 2 samples were within the normal limit for CRP. The mean SAA level was 121 times the upper normal limit at day 2 of fever onset, whereas the mean CRP level was 10 times the upper normal limit at the same time. SAA or anaphylatoxin C4a alone may lack specificity as a marker for PIR. However, the further analysis of samples obtained from CBT recipients by our method may provide fingerprints of markers useful for the diagnosis of PIR.
Identification of peak markers suggests that the SELDI-TOF MS system in combination with other proteomic methods could serve as a potential diagnostic tool in discovering biomarkers for PIR after CBT.
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